摘要
目的观察鲨鱼软骨素对晚期非小细胞肺癌的抗肿瘤作用。方法收集确诊为Ⅲb期和Ⅳ期非小细胞肺癌的患者56例,随机分为两组,均应用吉西他滨联合顺铂或单药多西他赛化疗,其中治疗组加服鲨鱼软骨素胶囊,观察其疗效、毒副作用及生存期,进行统计学分析。结果治疗组临床受益率(71.4%),对照组39.3%,差异有显著性(Uc=2.56,P<0.05)。治疗组和对照组毒副反应发生率分别为64.2%和71.4%,差异无显著性(χ2=0.33,P>0.05)。治疗组3年生存率为53.6%,对照组为21.4%,差异有显著性(χ2=6.17,P<0.05)。结论鲨鱼软骨素联合化疗治疗晚期非小细胞肺癌能明显提高有效率,降低毒副反应,提高患者生存率。
Objective To evaluate the therapeutic efficacy of shark chondroitin in treatment of the patients with advanced non-small cell lung cancer （NSCLC）. Methods Fifty-six pathology/cytology confirmed stage-Ⅲb or Ⅳ NSCLC patients were selected as eligible for this study. The patients were randomly divided into two groups： the control group received chemotherapy using either GP （gemcitabine and cisplatin） scheme or single drug of docetaxel, and the study group received shark chondroitin taken orally combined with the same chemotherapy scheme as used in the control group. The efficacy and side effects of treatment and survival rate of patients in both groups were observed. Results Compared with the control group, the clinical benefit response rate in study group improved markedly from 39. 3% to 71.4% （ Uc =2. 56, P 〈 0. 05）. The incidence of side effects was similar in both groups （64. 2% vs. 71.4%, X^2 =0. 33, P 〉0.05）. Overall patient survival rate after 3 years in the study group was 53.6% , which was significantly higher than the rate of 21.4% in control group, and the difference was significant （X^2 = 6. 17, P 〈 0. 05 ）. Conclusions Shark chondroitin combined with chemotherapy in the treatment of advanced NSCLC showed promising therapeutic efficacy, as indicated by improving clinical benefit response rate, decreasing side effects rate and prolonging the patients＇ survival time.
出处
《中国肿瘤临床与康复》
2009年第2期167-169,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
作者简介
刘克为，女，硕士，副主任医师，从事肿瘤内科专业。
